Welcome to our new site. THIS IS THE TEST SITE

BETA
The UK Clinical Trials Gateway has now been replaced with Be Part of Research. This is a new site which is still under development. Your feedback will help improve it.

Be part of research

We are here to help you find out about health and social care research that is taking place across the UK.

Real life stories

Harry

“Harry was well looked after, carefully monitored, and we felt supported by the staff every step of the way.”

Stephanie George and Lee Murdoch whose newborn son Harry took part in a study.  

Photo of infant child

Stephen

“Unless we try things out we’d never get to know what would work”.  

Stephen Burgess, rare cancer trial participant. 

Photo of man sitting in chair

Jane

“I wholeheartedly support clinical research. I wouldn’t be here enjoying an active life if it wasn’t for health research”.

Jane Owen, retired physiotherapist and Patient Research Ambassador

Photo of Jane Owen smiling

How to be involved

Video: There are many ways to get involved

Participating in research is not just about taking pills. Some research studies simply require you to complete a survey, attend a group with other patients, talk about something, try a new cream or treatment. There really is something for everyone.


Link to new animation - there's something for everyone

World diabetes day

Find out about all the research studies in the UK that are being carried out for Diabetes.  Connect with charities, NIHR specialist support and read stories of people who've taken part in diabetes research.

World diabetes day

Latest news


Combined drug therapy for at least 36 weeks reduces relapse after psychotic depression

Patients with psychotic depression who achieve remission benefit from continuing the antipsychotic drug olanzapine, alongside the antidepressant sertraline for at least a further four months, a North American trial has found. Patients who reduced and stopped olanzapine when their condition stabilised were more than twice as likely to relapse when compared with those who continued combined drug therapy. The majority of relapses occurred within two months of withdrawing olanzapine. This was a randomised control trial, with 126 participants. By 36 weeks from stabilisation, 13 people (20.3%) who were taking sertraline plus olanzapine and 34 people (54%) who were taking sertraline plus placebo experienced a relapse. These results suggest that continuation of combined drug therapy for these patients may help reduce the risks of potentially life-threatening relapse. The benefit needs to be balanced against the adverse effects of olanzapine, which include weight gain.

NIHR Signals
Combined drug therapy for at least 36 weeks reduces relapse after psychotic depression

Losing weight following type 2 diabetes diagnosis boosts chance of remission

People who lose at least 10% of their body weight in the first year after being diagnosed with type 2 diabetes increase their chances of being in remission after five years, compared with those whose weight remains stable. Losing this achievable amount of weight over the next four years also makes remission more likely. In this study of 867 people, 257 (30%) achieved remission at five-year follow-up. The participants had been taking part in a trial but had not received intensive lifestyle interventions or been put on extremely calorie-restricted diets. This NIHR-funded study strengthens the evidence that healthy behaviour change and weight loss can result in remission of type 2 diabetes. This finding may help to motivate people to lose weight soon after a diabetes diagnosis ─ setting realistic and achievable targets can make a difference in the longer term.

NIHR Signals
Losing weight following type 2 diabetes diagnosis boosts chance of remission

More health research news